Combination of LF and LSM using Fibroscan outperforms FIB-4 and LSM in patients with T2D easlfibronostg on June 29, 2026 Category: Publications Tag: Clinical Pathway, Diabetes, Identification, LIVERFASt, MASLD Post navigation Previous: Previous post: Association between Psoriasis severity and steatosis measured by LIVERFAStNext: Next post: Diagnostic performance of LIVERFASt as a non-invasive liver fibrosis test: data from three cohorts (JGLD manuscript)
